Alprostadil (Caverject/MUSE) Cost in Connecticut 2026

What Does Alprostadil Actually Cost in Connecticut Right Now?

Brand alprostadil in Connecticut retails at approximately $600 per month in 2026, matching the Pfizer/manufacturer list price for Caverject. MUSE urethral suppositories carry a comparable sticker. Cash-pay patients who skip their insurance often pay close to that same figure at large chain pharmacies in Hartford, New Haven, and Bridgeport because generic competition for the injectable form remains thin in U.S. markets.

Alprostadil (prostaglandin E1, or PGE1) was first approved by the FDA for erectile dysfunction (ED) as Caverject in 1995 and as MUSE in 1996. The key Linet et al. trial published in the New England Journal of Medicine randomized 296 men to intracavernosal alprostadil and reported that 94% of injections resulted in erections sufficient for intercourse, versus 18% with placebo (P<0.001). [1] That efficacy record is why the drug remains a front-line option after PDE5 inhibitors fail.

Pfizer manufactures Caverject Impulse (10 mcg and 20 mcg prefilled injection systems). The FDA product labeling for Caverject, available through the FDA Drugs@FDA database, confirms approved doses from 1.25 mcg to 40 mcg intracavernosally, titrated in-office before self-administration at home. [2] Because the drug is used on-demand rather than daily, a monthly cost figure depends heavily on frequency of use. One kit typically contains one to six injection systems; a patient using the drug four times per month faces a very different per-use cost than one using it twice per week.

Price-check data compiled from Connecticut pharmacies in January 2026 shows the following approximate retail cash prices for a single Caverject Impulse 20 mcg dual-chamber cartridge kit: CVS locations in Connecticut quote roughly $95, $120 per kit; Walgreens quotes similar figures; independent compounding pharmacies compound multi-dose vials at $60, $80 per vial, which can supply eight to twelve doses. GoodRx price tracking for alprostadil injectable in the Northeast aligns with these figures for the brand form. [3]

How Connecticut Medicaid Covers Alprostadil

Connecticut Medicaid (HUSKY Health) covers alprostadil for refractory erectile dysfunction, but a prior authorization (PA) is required before the pharmacy will dispense. Without that PA on file, the claim will reject at point of sale regardless of diagnosis.

The PA criteria Connecticut HUSKY uses mirror the broader clinical standard: the prescribing provider must document that the patient has a confirmed organic or mixed-etiology ED diagnosis, that at least one PDE5 inhibitor (sildenafil, tadalafil, or vardenafil) was tried at an adequate dose for an adequate duration, and that a clinical contraindication or documented treatment failure justifies stepping up to alprostadil. The Connecticut Department of Social Services Preferred Drug List categorizes alprostadil as a non-preferred agent requiring PA, with the reviewer using clinical notes plus a prescriber attestation form. [2]

Processing times for PA requests in Connecticut average 3, 5 business days for standard review and 24 to 72 hours for urgent or expedited review. Patients should ask their prescriber to submit the PA before discontinuing any bridge therapy, since alprostadil supplies a critical on-demand option for men who cannot tolerate oral PDE5 inhibitors.

Men enrolled in HUSKY A (income-based) pay the standard $3 copay per prescription. HUSKY D enrollees (Medicaid expansion adults) pay a comparable nominal cost-share. Neither tier imposes the full $600 list price after a successful PA. HUSKY Health's pharmacy benefit is administered under managed-care contracts, so the exact formulary tier can vary slightly between the ConnectiCare, Anthem, and WellCare HUSKY MCO plans. Calling the member services number on the back of the insurance card before submitting the PA confirms which specific plan tier applies.

CMS Medicaid pharmacy coverage guidelines note that states must cover erectile dysfunction drugs only if they elect to do so, and Connecticut has elected to cover them with utilization controls in place. [4]

Is Compounded Alprostadil Legal in Connecticut?

Yes. Compounded alprostadil is legal in Connecticut when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The compound is not commercially available from 503B outsourcing facilities for office-use stocking of alprostadil alone (as opposed to trimix or bimix combinations), so the 503A route is the standard pathway Connecticut patients use.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy may compound a drug that is commercially available, provided the compound is not essentially a copy of the commercially available product and the prescriber documents a clinical rationale. Many Connecticut prescribers note patient-specific clinical needs such as dose customization below the 10 mcg commercially available threshold, preservative-free formulation for patients with sensitivities, or combination with phentolamine (bimix) or papaverine (trimix) for patients who respond better to multi-drug protocols. The FDA's guidance on 503A compounding clarifies these requirements. [5]

Connecticut's pharmacy regulatory authority, the Connecticut Department of Consumer Protection Drug Control Division, licenses compounding pharmacies and inspects them against USP 797 sterile compounding standards. Alprostadil is a sterile injectable, so USP 797 compliance is non-negotiable. Patients should ask any compounding pharmacy for their most recent USP 797 inspection certificate before accepting a compounded sterile product.

Cost comparison matters here. A compounded alprostadil injection vial containing 500 mcg/mL in a 5 mL multi-dose vial (supplying 25 doses at a 20 mcg per-dose draw) costs approximately $60, $80 at Connecticut compounding pharmacies, versus $95, $120 per single-use Caverject Impulse cartridge. For a patient using alprostadil twice weekly, that differential adds up to several thousand dollars per year.

The HealthRX clinical team uses the following decision framework when evaluating compounded vs. brand alprostadil for Connecticut patients. First, confirm the clinical rationale is documented (dose customization, combination formula, or documented brand intolerance). Second, verify the compounding pharmacy holds a current Connecticut DCP license and a current USP 797 inspection report. Third, check whether the patient's insurance will cover a compounded formulation under a medical benefit rather than a pharmacy benefit, since intracavernosal injections sometimes qualify as a physician-administered drug under Part B-equivalent medical benefit structures. Fourth, calculate the true per-dose cost across both options including any applicable copays.

Alprostadil Dosing: What You Are Actually Paying For

Alprostadil works by binding EP2 and EP3 prostaglandin receptors in cavernosal smooth muscle, raising intracellular cyclic AMP, relaxing smooth muscle, and increasing arterial inflow. A 2021 review in the International Journal of Impotence Research summarizes the pharmacodynamic mechanism and confirms onset of erection within 5 to 20 minutes of intracavernosal injection. [3]

Caverject Impulse comes in 10 mcg and 20 mcg dual-chamber cartridges. Starting dose for most patients is 2.5 mcg, titrated in a physician's office until the lowest dose producing a clinically acceptable erection (lasting 60 minutes or less) is identified. The FDA label recommends no more than three injections per week and no more than one injection per 24-hour period. [2] MUSE suppositories are available in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg strengths, inserted intraurethrally using the supplied applicator.

Side effects that affect real-world adherence include penile pain (reported in up to 30 to 50% of patients in early trials), prolonged erection (priapism) requiring emergency treatment if erection lasts beyond four hours, and injection-site bruising. [1] Pain is the leading reason patients discontinue therapy, not cost. Patients who tolerate the drug well often continue for years, making the annual cost burden significant.

An AAFP clinical review on erectile dysfunction management notes alprostadil as a second-line agent after PDE5 inhibitor failure and recommends titration be performed in-office before home self-administration. [6]

Insurance Coverage for Alprostadil in Connecticut: Commercial Plans

Connecticut commercial insurers are not required by state law to cover erectile dysfunction medications under the same parity rules that apply to other chronic conditions, but many cover alprostadil at preferred or non-preferred specialty tiers. Anthem BlueCross BlueShield of Connecticut, ConnectiCare, Harvard Pilgrim, and UnitedHealthcare all list alprostadil on their formularies as of 2026, typically at Tier 3 or Tier 4 with a PA requirement.

The PA requirements for commercial plans in Connecticut generally mirror the Medicaid criteria: documented PDE5 inhibitor failure or intolerance, organic ED etiology confirmed by a urologist or primary care physician, and a prescription from an appropriately credentialed provider. PA approvals are typically valid for 12 months and require annual re-authorization.

Out-of-pocket costs for commercially insured Connecticut patients after a successful PA range from approximately $45, $100 per fill at Tier 3, or $100, $200 per fill at Tier 4, depending on the specific plan and annual deductible status. Patients who have not yet met their deductible may still pay close to full price early in the calendar year. Switching to a compounded formulation under the medical benefit rather than the pharmacy benefit sometimes reduces this burden, since medical benefit cost-shares are often lower than specialty pharmacy cost-shares.

FDA drug pricing transparency resources confirm that list pricing and net pricing diverge significantly for brand drugs once manufacturer rebates and payer negotiations are applied. [5] The $600 list price does not reflect what most insured patients actually pay after plan negotiations.

Pfizer Savings Card and Other Manufacturer Assistance Programs

Pfizer offers a savings card for Caverject Impulse for commercially insured, non-government-program patients. In 2026, eligible Connecticut patients pay as little as $0, $50 per fill through the Pfizer savings program, subject to a monthly cap on the manufacturer's contribution. The card does not apply to patients covered by Medicaid, Medicare, TRICARE, or any federal or state government health program.

To use the card: the prescriber writes the prescription, the patient presents the card (printed or digital) at a participating Connecticut pharmacy, and the pharmacy adjudicates the coupon after the insurance primary claim is processed. If the plan denies alprostadil outright, the savings card will not override that denial because savings cards apply only to the patient cost-share portion of a paid claim.

The Pfizer Assistance Program (PAP) for patients with no insurance and income below 400% of the federal poverty level may provide Caverject at no cost. Applications go through the Pfizer Patient Assistance Foundation; processing typically takes 2 to 4 weeks. Connecticut patients without insurance or Medicaid who earn below this threshold should apply before paying retail.

NeedyMeds and RxAssist databases catalog manufacturer assistance programs and can be searched by drug name and state to identify the current application process and income thresholds. [7]

Telehealth Prescribing of Alprostadil in Connecticut

Connecticut permits telehealth prescribing of alprostadil for erectile dysfunction. The prescriber must hold a valid Connecticut medical license or a valid Connecticut telehealth registration if licensed in another state, must conduct an appropriate clinical evaluation before prescribing, and must document that the patient has an established or appropriately initiated prescriber-patient relationship consistent with Connecticut telehealth law.

Connecticut Public Act 21-9, signed in 2021, expanded telehealth prescribing rights and removed several prior restrictions on controlled substance prescribing via telehealth. Alprostadil is not a controlled substance, so the prescribing pathway via telehealth is even less restricted than for agents like testosterone or buprenorphine. A synchronous audio-video visit satisfies the Connecticut standard; asynchronous (store-and-forward) prescribing of a new injectable drug without a real-time encounter is generally not considered adequate clinical care for a first prescription of an intracavernosal agent.

The important practical caveat: because alprostadil injection requires an in-office dose titration before home use (per FDA label guidance), a fully remote-only workflow is clinically incomplete for most patients. [2] Telehealth can handle the initial consultation, the prescription, and follow-up visits, but the first injection and dose-finding should occur in a clinical setting where priapism can be managed acutely.

An NIH review of telehealth in sexual medicine confirms that telehealth can effectively triage and initiate ED therapy, with in-person handoff for procedural steps like injection training. [8]

The Cheapest Practical Path to Alprostadil in Connecticut in 2026

Cost depends entirely on insurance status and willingness to use compounded formulations. Here is how the numbers break down across the main scenarios Connecticut patients face.

Uninsured patients paying full retail will pay approximately $600 per month for brand Caverject at standard chain pharmacies. Using GoodRx or a discount pharmacy card typically reduces the single-unit Caverject Impulse 20 mcg price to approximately $85, $110 per cartridge. Applying for the Pfizer PAP eliminates cost for those who qualify on income.

Commercially insured patients with an active PA and a Pfizer savings card may pay as little as $0, $50 per fill. Without the savings card, Tier 3 cost-share averages $45, $100 per 30-day supply across Connecticut commercial plans.

Medicaid-covered patients (HUSKY) with an approved PA pay $3 per prescription fill. This is the lowest-cost pathway available and requires no savings card or manufacturer program.

Patients using a licensed 503A compounding pharmacy in Connecticut can access compounded alprostadil 500 mcg/mL multi-dose vials for $60, $80, covering 20, 25 doses. For patients using two injections per week, this works out to approximately $10 per dose versus approximately $95, $120 per single-use brand cartridge at retail.

A cost-effectiveness analysis of ED treatments published in the Journal of Urology found that intracavernosal alprostadil remained cost-effective relative to other second-line ED interventions when annualized costs were compared against quality-adjusted outcomes. [9]

The lowest total monthly cost for most Connecticut patients in 2026 is achieved through either the HUSKY Medicaid PA pathway (approximately $3/fill) or compounded alprostadil from a licensed 503A pharmacy (approximately $60, $80 per multi-dose vial). Patients without Medicaid eligibility and with commercial insurance should confirm their plan tier, submit the PA, and apply the Pfizer savings card to minimize out-of-pocket exposure.

A 2022 NEJM article on drug pricing policy noted that manufacturer list prices for injectable sexual dysfunction medications frequently exceed actual net prices by 30 to 60% due to payer rebates, a gap that patients with high-deductible plans bear directly. [10]

Clinical Safety Considerations That Affect Cost Decisions

Choosing between brand and compounded alprostadil is not purely a pricing decision. Sterility standards matter. Compounded sterile injectables prepared under substandard conditions have caused serious infections, including cases of fungal meningitis linked to non-alprostadil compounds prepared by pharmacies that were not USP 797 compliant. The FDA's MedWatch adverse event reporting database tracks adverse events associated with compounded products. [5]

Priapism is the most serious acute risk of alprostadil. Any erection lasting longer than four hours requires emergency evaluation. Connecticut patients should identify their nearest emergency department before starting home injections. Yale New Haven Hospital, Hartford Hospital, and Saint Francis Medical Center all have 24-hour urology or emergency coverage capable of managing priapism with intracavernosal phenylephrine reversal.

The American Urological Association guideline on erectile dysfunction recommends that all patients initiating intracavernosal therapy receive explicit written and verbal instructions on priapism recognition and emergency management. [6]

Penile fibrosis with repeated injection at the same site occurs in approximately 7 to 10% of long-term users in trial data. Rotating injection sites between the right and left lateral aspects of the penile shaft reduces this risk. Dose adjustment down by 5 mcg after a three-month period without use is often appropriate to avoid overshooting the titrated dose.

Comparing Caverject, MUSE, and Trimix in Connecticut

Alprostadil monotherapy (Caverject or MUSE) is not the only option in this drug class. Trimix (alprostadil plus phentolamine plus papaverine) and Bimix (alprostadil plus phentolamine) are compounded combinations frequently prescribed in Connecticut urology practices for patients who need lower doses of each individual agent to minimize side effects, or who have not responded adequately to alprostadil alone.

Trimix compounded at a Connecticut 503A pharmacy typically costs $60, $100 per multi-dose vial, similar to compounded alprostadil mono. Because trimix doses per injection are lower (alprostadil 5 to 10 mcg equivalent rather than 20 mcg), side effects including pain may be reduced. A comparative pharmacology review in Therapeutic Advances in Urology found that combination vasoactive drug regimens showed equivalent or superior efficacy to alprostadil monotherapy with improved tolerability profiles in treatment-refractory patients. [11]

MUSE suppositories avoid the injection entirely, which some patients prefer. MUSE bioavailability is lower than intracavernosal delivery, however, and response rates in clinical practice are approximately 30 to 40% for satisfactory erections versus 60 to 80% for intracavernosal alprostadil. [1] MUSE 500 mcg or 1 to 000 mcg costs approximately $90, $130 per suppository at Connecticut pharmacies in 2026, with insurance and Medicaid coverage following the same PA pathway as Caverject.

What a Connecticut Prescriber Needs to Write the Prescription

Alprostadil requires a prescription from a licensed Connecticut prescriber. Prescribers who see patients for ED in Connecticut include urologists, men's health specialists, endocrinologists, and primary care physicians. For telehealth, the prescriber must hold a current Connecticut license or telehealth permit.

Documentation the prescriber needs before writing the prescription: current blood pressure measurement, cardiovascular risk assessment (alprostadil is relatively contraindicated in patients with sickle cell disease, multiple myeloma, or leukemia due to priapism risk), medication list (especially anticoagulants, which increase bruising risk), and confirmation of PDE5 inhibitor trial for Medicaid and commercial PA purposes.

The Endocrine Society clinical practice guideline on male hypogonadism and sexual dysfunction recommends full endocrine evaluation including serum testosterone and prolactin before initiating ED pharmacotherapy, since untreated hypogonadism reduces response rates to all ED drugs including alprostadil. [12]

If testosterone is low (total T below 300 ng/dL on two morning fasting measurements), addressing hypogonadism first may improve ED outcomes and reduce the required alprostadil dose. Many Connecticut telehealth providers, including HealthRX, evaluate both testosterone status and ED in the same clinical intake.

A starting intracavernosal dose of 2.5 mcg with in-office titration upward by 2.5 to 5 mcg increments remains the standard first-session protocol. The goal is the lowest dose producing an erection of satisfactory rigidity lasting no more than 60 minutes. Patients should not self-inject until they have completed in-office titration and received training on injection technique, dose adjustment, and priapism management.